Open AccessPleiotropic anti-myeloma activity of ITF2357: inhibition of interleukin-6 receptor signaling and repression of miR-19a and miR-19b
Author(s) -
Katia Todoerti,
Valentina Barbui,
Olga Pedrini,
Marta Lionetti,
Gianluca Fossati,
Paolo Mascagni,
Alessandro Rambaldi,
Antonino Neri,
Martino Introna,
Luigia Lombardi,
Josée Golay
Publication year - 2009
Publication title -
haematologica
Language(s) - English
Resource type - Journals
SCImago Journal Rank - 2.782
H-Index - 142
eISSN - 1592-8721
pISSN - 0390-6078
DOI - 10.3324/haematol.2009.012088
Subject(s) - interleukin 6 receptor , biology , receptor , microbiology and biotechnology , cell culture , multiple myeloma , signal transduction , gene expression , interleukin 6 , gene , microrna , cancer research , cytokine , immunology , genetics
The histone deacetylase inhibitor ITF2357 has potent cytotoxic activity in multiple myeloma in vitro and has entered clinical trials for this disease.